CN104352511A - Oral ulcer paste for patients with agranulocytosis and preparation method thereof - Google Patents

Oral ulcer paste for patients with agranulocytosis and preparation method thereof Download PDF

Info

Publication number
CN104352511A
CN104352511A CN201410596422.XA CN201410596422A CN104352511A CN 104352511 A CN104352511 A CN 104352511A CN 201410596422 A CN201410596422 A CN 201410596422A CN 104352511 A CN104352511 A CN 104352511A
Authority
CN
China
Prior art keywords
parts
vitamin
pulverizing
ulcer
oral ulcer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410596422.XA
Other languages
Chinese (zh)
Inventor
高广勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fourth Military Medical University FMMU
Original Assignee
Fourth Military Medical University FMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fourth Military Medical University FMMU filed Critical Fourth Military Medical University FMMU
Priority to CN201410596422.XA priority Critical patent/CN104352511A/en
Publication of CN104352511A publication Critical patent/CN104352511A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to oral ulcer paste for patients with agranulocytosis. The oral ulcer paste comprises the following ingredients: 15-25 parts of glycerinum, 1000-3000m parts of nystatin, 25-35 parts of Vitamin B6 powder, 10-20 parts of Vitamin B2 powder, 100-300 parts of Vitamin C powder, 100-300 parts of metronidazole powder and 0.3-0.7 part of 0.1% lidocaine hydrochloride. The preparation steps of the oral ulcer paste are as follows: the ingredients are mixed according to a formula ratio and then are refrigerated at 4-8 DEG C, and the oral ulcer paste is used within 48 hours. The oral ulcer paste has the characteristics of being high in cure rate and short in healing time, reducing the pain of patients, and being easily prepared.

Description

A kind of agranulocytosis patient Stomatic ulcer paste and preparation method thereof
Technical field
The invention belongs to medical art, be specifically related to a kind of agranulocytosis patient Stomatic ulcer paste and preparation method thereof.
Background technology
Malignant tumor patient is leukaemic's chemotherapeutic period particularly, has more existing agranulocytosis, and during agranulocytosis, some patients there will be oral ulcer.Domestic literature is reported, after Chemotherapy in Malignant Carcinoma Patients, oral cavity ulcer rates is 66% ~ 75%, and foreign literature reports that its incidence rate is 40% ~ 90%.Oral ulcer is usually expressed as oral mucosa edema, ulcer, pain, dysphagia, hoarseness, severe patient can reduce because of feed, amount of drinking water and cause water, electrolyte balance imbalance and malnutrition, bring considerable distress to patient, and be unfavorable for the recovery of disease.Therefore, how to alleviate patient suffering, promote that the quickly-healing of ulcer is urgent problem.
Agranulocytosis patient oral ulcer main cause is that chemotherapy has direct detrimental effect, immune dysfunction to Buccal mucosa cell, body constitution declines, also with patient infection, heating, poor appetite, do not have enough sleep, psychentonia, pressure is excessive, neuroendocrine disorders, and electrolytes and minerals lacks relevant.
The many considerations of agranulocytosis patient oral ulcer local infection factor are in Abwehrkraft des Koepers reduction or when having serious underlying diseases, prolonged application broad ectrum antibiotic and hormone, and fungus amount reproduction, causes oral cavity infection, and forms ulcer.The compound infective agent of the many considerations of oral ulcer exists simultaneously, and comprise antibacterial and fungal infection, bacteriological infection is based on anaerobic infection, and fungal infection is mainly based on monilial infection.
The cause of disease of oral ulcer is more complicated, and have multifactor participation to fall ill, therefore clinical treatment according to different inducements, will be treated pointedly, the curative effect that could obtain.As: remove the pressure of psychentonia, calmness, sleeping etc.; Increase the resistance of body, for ulcer local, local can be adopted to embrocate pain relieving, antiinflammatory, the medicine of Promotive union.As: cod-liver oil paste, prednisone paste, ulcer ointment etc., or local anaesthetics is embrocated, to ease the pain in front local on the feed.
Existing oral ulcer posts hormones, mainly pastes mainly for bacteriological infection for immune-related oral ulcer, antibiotics such as chlortetracycline oral ulcer.Cydiodine buccal tablet has powerful sterilization antisepsis, but it is strong to have zest, easily irritated, the not easily feature of life-time service.Chinese medicine preparation oral cavity ulcer powder mainly has effect of heat-clearing and toxic substances removing sore.There is no one at present about the bibliographical information of mix preparation and the patent of invention of how to treat agranulocytosis patient oral ulcer.Main to treat protopathy, whole body support and local anti symptom treatment clinically.
Summary of the invention
In order to overcome above-mentioned the deficiencies in the prior art, the object of the present invention is to provide a kind of agranulocytosis patient Stomatic ulcer paste and preparation method thereof, having the advantages that cure rate is high, healing time is short, reduce patient pain's sense and easily preparation.
To achieve these goals, the technical solution used in the present invention is: a kind of agranulocytosis patient Stomatic ulcer paste, includes following component:
Glycerol 15-25 part;
Nystatin 1000-3000m part;
Vitamin B6 sheet pulverizing 25-35 part;
Vitamin B2 sheet pulverizing 10-20 part;
VITAMIN C TABLET pulverizing 100-300 part;
Metronidazole Tablet pulverizing 100-300 part;
Lidocaine hydrochloride 0.3-0.7 part of 0.1%.
A preparation method for agranulocytosis patient Stomatic ulcer paste, comprises the following steps:
By glycerol 15-25 part; Nystatin 1000-3000m part; Vitamin B6 Tablets pulverizing 25-35 part; Vitamin B2 sheet pulverizing 10-20 part; VITAMIN C TABLET pulverizing 100-300 part; Metronidazole Tablet pulverizing 100-300 part; Lidocaine hydrochloride 0.3-0.7 part of 0.1%, after formula proportion mixing, is placed in 4-8 DEG C of cold preservation, uses, be applied to affected part, oral cavity in 48 hours.
Wherein Metronidazole Tablet has the effect of anaerobe resistant, and nystatin suppresses oral cavity monilial infection, and vitamin B6, vitamin B2 and vitamin C can supplement the vitamin needed for cell migration, and lignocaine local action, the pain of patient can be improved.
Beneficial effect of the present invention:
This Stomatic ulcer paste significantly can shorten oral ulcer patient healing, improves the effective percentage of patient's dental ulcer treatment.Have the advantages that cure rate is high, healing time is short, reduce patient pain's sense and easily preparation.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is described in further detail.
Embodiment 1
A kind of agranulocytosis patient Stomatic ulcer paste, includes following component:
Glycerol 15 parts; Nystatin 1000 parts; Vitamin B6 Tablets pulverizing 25 parts; Vitamin B2 sheet pulverizing 10 parts; VITAMIN C TABLET pulverizing 100 parts; Metronidazole Tablet pulverizing 100 parts; The lidocaine hydrochloride of 0.1% 0.3 part.
Embodiment 2
A kind of agranulocytosis patient Stomatic ulcer paste, includes following component:
Glycerol 20 parts; Nystatin 2000 parts; Vitamin B6 Tablets pulverizing 30 parts; Vitamin B2 sheet pulverizing 15 parts; VITAMIN C TABLET pulverizing 200 parts; Metronidazole Tablet pulverizing 200 parts; The lidocaine hydrochloride of 0.1% 0.5 part.
Embodiment 3
A kind of agranulocytosis patient Stomatic ulcer paste, includes following component:
Glycerol 25 parts; Nystatin 3000 parts; Vitamin B6 Tablets pulverizing 35 parts; Vitamin B2 sheet pulverizing 20 parts; VITAMIN C TABLET pulverizing 300 parts; Metronidazole Tablet pulverizing 300 parts; The lidocaine hydrochloride of 0.1% 0.7 part.
Embodiment 4
Stomatic ulcer paste compound method, comprises the following steps:
Get Vitamin B6 Tablets 30 parts, vitamin B2 sheet 15 parts, VITAMIN C TABLET 200 parts and Metronidazole Tablet 200 parts, nystatin 2000 parts grinds to form powdery respectively, is mixed in glycerol 20 parts, adds 0.1% lidocaine hydrochloride injection 0.5 part, be placed in 4-8 DEG C of cold preservation for subsequent use, use in 48 hours.
Clinical data
Case is originated: occur stage of bone marrow after getting my institute's leukemia, lymphoma, myeloma chemotherapy.Neutrophilic granulocyte is lower than 0.5x10 9/ L, and there is oral ulcer patient 80 example, in the middle of patient, oral ulcer grade distributes in following ratio.Wherein man 42 example, female 38 example, at 16 ~ 68 years old age, the median age 41.2 years old, wherein matched group patient 30 example, gives suit the medicine to the illness Supporting Therapy and common mouth care, and experimental group 50 example, gives Stomatic ulcer paste process.
The classification of oral ulcer: the acute and subacute toxicity reaction calibration standard with reference to WHO anticarcinogen, divides 5 degree by oral ulcer according to the weight extent of reaction.0 degree: mucosa is normal; I degree: erythroplakia, pain, does not affect feed; II degree: erythroplakia is obvious, and pain increases the weight of, and is dispersed in ulcer, can enter semi-liquid diet; III degree: mucosal ulcer and pain more obvious than II degree, can only liquid diet be entered; IV degree: sharp ache, ulcer is fused into large lamellar, can not take food.
Criterion of therapeutical effect
Effective: within treatment 3d, completely, pain hyperemia waits transference cure: effectively in oral ulcer healing: within treatment 3d, oral ulcer reduces obviously, and pain congestive symptom alleviates obviously, and within 7d, ulcer heals substantially, and pain congestive symptom disappears;
Minor effect: after treatment 3d, the symptom such as ulcer area, pain, hyperemia is without significant change, after 7d, the symptom such as ulcer area, pain, hyperemia makes moderate progress;
Invalid: after treatment 7d, the symptom such as ulcer area, pain, hyperemia is without any improvement.
Effective percentage is obvious effective rate and effective percentage sum.
Drug usage and grouping
1) usage matched group gives conventional mouth care, uses sodium peroxide solution (1%) to clean oral cavity, and rinsing the mouth sodium bicarbonate solution (1.5%).The invention described above invention example 2 is prepared Stomatic ulcer paste local obliterating in oral ulcer affected part by experimental group on the basis of conventional oral care, 4 times/d.Each consumption about 1ml.
2) experiment grouping: experimental group (50 example):
I degree oral ulcer is totally 10 examples;
II degree oral ulcer is totally 20 examples;
III degree oral ulcer is totally 10 examples;
IV degree oral ulcer is totally 10 examples;
Matched group (30 example)
I degree oral ulcer is totally 6 examples;
II degree oral ulcer is totally 10 examples;
III degree oral ulcer is totally 7 examples;
IV degree oral ulcer is totally 7 examples;
3) the oral cavity healing time of every patient is recorded
Result
1) experimental group and matched group oral cavity healing time
Found that experimental group I degree healing time, II degree healing time, III degree healing time and IV degree healing time are all remarkable in matched group, there is remarkable statistical significance, P < 0.05.In table 1.
2) two groups of comparitive study
The effective percentage of the ulcer treatment of experimental group is 92%.
The effective percentage of the ulcer treatment of matched group is 70%, and experimental group is apparently higher than matched group.In table 2.
Table 1. liang group different stage oral ulcer healing time (mean ± SD)
Table 2. experimental group and matched group effective percentage compare
Group n Effective Effectively Minor effect Invalid
Experimental group 50 19 27 3 1
Matched group 30 7 14 6 3
Animal toxicology experiment of the present invention:
Experiment purpose: observe animal acute toxicity of the present invention reaction, measure animal half lethal dose and maximum tolerated dose
Animal: BALB/c mouse, is provided by The Fourth Military Medical University's animal experimental center, and male and female quantity is equal.
Medicine: example 2 compounding pharmaceutical of the present invention.
Route of administration: gastric infusion.
Method: each 18 of BALB/c mouse male and female, weighs, labelling.Feeding environment is humidity: 25 ± 2 DEG C, relative humidity 63-67%.
According to drug level, experiment is divided into 3 groups,
A group is: get example 2 compounding pharmaceutical 20 parts of the present invention (drug containing: glycerol 20 parts, nystatin 2000 parts; Vitamin B6 Tablets pulverizing 30 parts; Vitamin B2 sheet pulverizing 15 parts; VITAMIN C TABLET pulverizing 200 parts; Metronidazole Tablet pulverizing 200 parts; The lidocaine hydrochloride of 0.1% 0.5 part);
B group is: get compounding pharmaceutical 20 parts (drug containing: glycerol 20 parts, nystatin 4000 parts in proportion; Vitamin B6 Tablets pulverizing 60 parts; Vitamin B2 sheet pulverizing 30 parts; VITAMIN C TABLET pulverizing 400 parts; Metronidazole Tablet pulverizing 400 parts; The lidocaine hydrochloride of 0.1% 1 part);
C group is: get compounding pharmaceutical 20 parts (drug containing: glycerol 20 parts, nystatin 8000 parts in proportion; Vitamin B6 Tablets pulverizing 120 parts; Vitamin B2 sheet pulverizing 60 parts; VITAMIN C TABLET pulverizing 800 parts; Metronidazole Tablet pulverizing 800 parts; The lidocaine hydrochloride of 0.1% 2 parts);
Each assembly paste producing agent is dissolved in 40 parts of distilled water respectively, before gavage, Ultrasound Instrument is ultrasonic, form 33.3% suspension, 1ml syringe No. 12 gavage syringe needle gavages, often organize each 6 of mice male and female, under mice fasted conditions, (be equivalent to example 2 compounding pharmaceutical 0.1ml/10g, 0.2ml/10g, 0.4ml/10g respectively by 0.3ml/10g body weight gavage; 600,1200,2400 times of adult human dose, adult calculates by average 60kg), 1 time/8 hours, after gavage, mice put into Animal Lab., conventionally raised, and freely drank water and activity.Continuous 5 days, continuous observation 15 days, observed mice physiology and dystropy.
Result: 3 groups of totally 36 BALB/c mouse period in a medicine and taking medicine latter 15 days, all dead mouse do not occur, physiological activity and the equal no exceptions of behavior.
Conclusion: adopt the present invention to prepare Stomatic ulcer paste and give mouse stomach, 600,1200,2400 times that give that dosage is adult human dose, all there is not death and dystropy in mice.

Claims (5)

1. an agranulocytosis patient Stomatic ulcer paste, is characterized in that, comprises following component:
Glycerol 15-25 part;
Nystatin 1000-3000m part;
Vitamin B6 Tablets pulverizing 25-35 part;
Vitamin B2 sheet pulverizing 10-20 part;
VITAMIN C TABLET pulverizing 100-300 part;
Metronidazole Tablet pulverizing 100-300 part;
Lidocaine hydrochloride 0.3-0.7 part of 0.1%.
2. a kind of agranulocytosis patient Stomatic ulcer paste according to claim 1, is characterized in that, comprise following component:
Glycerol 15 parts; Nystatin 1000 parts; Vitamin B6 Tablets pulverizing 25 parts; Vitamin B2 sheet pulverizing 10 parts; VITAMIN C TABLET pulverizing 100 parts; Metronidazole Tablet pulverizing 100 parts; The lidocaine hydrochloride of 0.1% 0.3 part.
3. a kind of agranulocytosis patient Stomatic ulcer paste according to claim 1, is characterized in that, comprise following component:
Glycerol 20 parts; Nystatin 2000 parts; Vitamin B6 Tablets pulverizing 30 parts; Vitamin B2 sheet pulverizing 15 parts; VITAMIN C TABLET pulverizing 200 parts; Metronidazole Tablet pulverizing 200 parts; The lidocaine hydrochloride of 0.1% 0.5 part.
4. a kind of agranulocytosis patient Stomatic ulcer paste according to claim 1, is characterized in that, comprise following component:
Glycerol 25 parts; Nystatin 3000 parts; Vitamin B6 Tablets pulverizing 35 parts; Vitamin B2 sheet pulverizing 20 parts; VITAMIN C TABLET pulverizing 300 parts; Metronidazole Tablet pulverizing 300 parts; The lidocaine hydrochloride of 0.1% 0.7 part.
5. a preparation method for agranulocytosis patient Stomatic ulcer paste, is characterized in that, comprises the following steps:
By glycerol 15-25 part; Nystatin 1000-3000m part; Vitamin B6 Tablets pulverizing 25-35 part; Vitamin B2 sheet pulverizing 10-20 part; VITAMIN C TABLET pulverizing 100-300 part; Metronidazole Tablet pulverizing 100-300 part; Lidocaine hydrochloride 0.3-0.7 part of 0.1%, after formula proportion mixing, is placed in 4-8 DEG C of cold preservation, uses in 48 hours.
CN201410596422.XA 2014-10-31 2014-10-31 Oral ulcer paste for patients with agranulocytosis and preparation method thereof Pending CN104352511A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410596422.XA CN104352511A (en) 2014-10-31 2014-10-31 Oral ulcer paste for patients with agranulocytosis and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410596422.XA CN104352511A (en) 2014-10-31 2014-10-31 Oral ulcer paste for patients with agranulocytosis and preparation method thereof

Publications (1)

Publication Number Publication Date
CN104352511A true CN104352511A (en) 2015-02-18

Family

ID=52519884

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410596422.XA Pending CN104352511A (en) 2014-10-31 2014-10-31 Oral ulcer paste for patients with agranulocytosis and preparation method thereof

Country Status (1)

Country Link
CN (1) CN104352511A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111110831A (en) * 2020-02-20 2020-05-08 柳州市工人医院 Ulcer paste and preparation method thereof
CN112891295A (en) * 2021-01-29 2021-06-04 陕西中鸿科瑞再生医学研究院有限公司 Exosome mouthwash as well as preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856101A1 (en) * 1998-12-04 2000-06-08 Labtec Gmbh Patch for local administration of drugs in the oral cavity includes a drug-containing matrix comprising a water-insoluble cellulose ether and a water-soluble cellulose ether in a defined ratio
CN101721457A (en) * 2009-11-03 2010-06-09 杨文臣 Medicine for treating oral ulcer
CN103083649A (en) * 2012-09-25 2013-05-08 中国人民解放军第三军医大学第一附属医院 Chewing gum for preventing and treating oral ulcer resulted from chemotherapy
CN103638039A (en) * 2013-12-27 2014-03-19 付茜 Rinse solution

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856101A1 (en) * 1998-12-04 2000-06-08 Labtec Gmbh Patch for local administration of drugs in the oral cavity includes a drug-containing matrix comprising a water-insoluble cellulose ether and a water-soluble cellulose ether in a defined ratio
CN101721457A (en) * 2009-11-03 2010-06-09 杨文臣 Medicine for treating oral ulcer
CN103083649A (en) * 2012-09-25 2013-05-08 中国人民解放军第三军医大学第一附属医院 Chewing gum for preventing and treating oral ulcer resulted from chemotherapy
CN103638039A (en) * 2013-12-27 2014-03-19 付茜 Rinse solution

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
张英泽 等: "《临床用药处方手册》", 30 June 2005, 中国新闻联合出版社 *
李定印: "利多卡因加复合维生素B 和制霉菌素治疗儿童口腔溃疡临床观察", 《实用医技杂志》 *
杨列霞 等: "甲硝唑及维生素C 雾化治疗口腔溃疡", 《护理研究》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111110831A (en) * 2020-02-20 2020-05-08 柳州市工人医院 Ulcer paste and preparation method thereof
CN111110831B (en) * 2020-02-20 2023-08-08 柳州市工人医院 Ulcer paste and preparation method thereof
CN112891295A (en) * 2021-01-29 2021-06-04 陕西中鸿科瑞再生医学研究院有限公司 Exosome mouthwash as well as preparation method and application thereof

Similar Documents

Publication Publication Date Title
EP3257508A1 (en) Application of chlorogenic acid in preparing medicines for treating melanoma and medicines for treating melanoma
JP2016530281A (en) Composition for prevention and treatment of cancer-related fatigue comprising processed ginseng powder or processed ginseng extract with increased ginsenoside component
CN111870609A (en) Intestinal flora regulator and application thereof
US9901602B2 (en) Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc
CN104352511A (en) Oral ulcer paste for patients with agranulocytosis and preparation method thereof
CN105380956B (en) A kind of pharmaceutical composition of Dana Delany containing Chinese mugwort for treating leukaemia and application
CN104322985A (en) Piglet feed
TW202015549A (en) Muscle-differentiation promoting action of ergothioneine, ascorbic acid 2-glucoside, ascorbic acid, and combinations thereof
CN104642256A (en) Fifty-fifty pig-raising method
CN101049345A (en) A preparation for treating disease of oral cavity and gorge, and preparation method
CN113521253A (en) Compound mouthwash
CN100556448C (en) Chinese medicine pharmaceutical composition of a kind of inhibition and treatment tumor and its production and application
CN102940771B (en) Traditional Chinese medicine for promoting breast milk secretion
WO2022222388A1 (en) Use of l-sorbose in preparation of drug for treating tumors
CN103272068B (en) Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof
CN103800341A (en) Combined medicine for preventing and treating tumors
JP5717224B1 (en) Powdered functional food and method for producing the same
CN117281846B (en) Traditional Chinese medicine composition for improving hypoxia tolerance and preparation method and application thereof
CN102885293A (en) Spirulina health food and preparation method
CN107019771A (en) A kind of antineoplastic Chinese medicine composition
CN104147056B (en) Composition containing bromhexine hydrochloride
TWI615147B (en) The new uses of black garlic in improving male animal semen quality and as health food products to better sexual dysfunction
CN103638021A (en) Preparation method for pidotimod oral liquid
CN104524352A (en) Traditional Chinese medicine for invigorating spleen and increasing appetite for animals
CN103933085A (en) Method for treating Escherichia coli infection diseases by using creat and fosfomycin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150218

RJ01 Rejection of invention patent application after publication